Q1 Earnings Estimate for Stereotaxis Issued By Roth Capital

Stereotaxis, Inc. (NYSEAMERICAN:STXS) – Stock analysts at Roth Capital lowered their Q1 2025 EPS estimates for shares of Stereotaxis in a report issued on Tuesday, March 4th. Roth Capital analyst J. Wittes now forecasts that the company will earn ($0.07) per share for the quarter, down from their previous estimate of ($0.01). The consensus estimate for Stereotaxis’ current full-year earnings is ($0.26) per share. Roth Capital also issued estimates for Stereotaxis’ Q2 2025 earnings at ($0.08) EPS, Q4 2025 earnings at ($0.08) EPS, FY2025 earnings at ($0.30) EPS and FY2026 earnings at ($0.07) EPS.

Stereotaxis Trading Up 2.8 %

NYSEAMERICAN STXS opened at $1.85 on Thursday. The company has a market cap of $156.75 million, a P/E ratio of -6.61 and a beta of 1.54. Stereotaxis has a 1 year low of $1.66 and a 1 year high of $3.29. The business’s fifty day moving average price is $2.27.

Hedge Funds Weigh In On Stereotaxis

Several institutional investors have recently modified their holdings of the stock. Traynor Capital Management Inc. acquired a new position in Stereotaxis during the fourth quarter worth $366,000. Charles Schwab Investment Management Inc. grew its position in Stereotaxis by 10.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 167,297 shares of the company’s stock worth $341,000 after buying an additional 15,491 shares in the last quarter. State Street Corp increased its holdings in Stereotaxis by 5.7% in the 3rd quarter. State Street Corp now owns 680,612 shares of the company’s stock valued at $1,388,000 after buying an additional 36,518 shares during the period. Barclays PLC lifted its position in shares of Stereotaxis by 449.9% during the 3rd quarter. Barclays PLC now owns 101,953 shares of the company’s stock worth $208,000 after buying an additional 83,412 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in Stereotaxis by 7.2% in the third quarter. Geode Capital Management LLC now owns 1,391,718 shares of the company’s stock valued at $2,840,000 after buying an additional 93,253 shares in the last quarter. 45.35% of the stock is currently owned by institutional investors and hedge funds.

About Stereotaxis

Stereotaxis, Inc designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites.